Please use this identifier to cite or link to this item:
DC FieldValue
dc.titleBurden and Cost of Hospitalization for Respiratory Syncytial Virus in Young Children, Singapore
dc.contributor.authorTam, C.C.
dc.contributor.authorTam, C.C.
dc.contributor.authorTam, C.C.
dc.contributor.authorTam, C.C.
dc.contributor.authorYeo, K.T.
dc.contributor.authorYeo, K.T.
dc.contributor.authorTee, N.
dc.contributor.authorTee, N.
dc.contributor.authorLin, R.
dc.contributor.authorMak, T.M.
dc.contributor.authorThoon, K.C.
dc.contributor.authorThoon, K.C.
dc.contributor.authorThoon, K.C.
dc.contributor.authorJit, M.
dc.contributor.authorYung, C.F.
dc.contributor.authorYung, C.F.
dc.contributor.authorYung, C.F.
dc.identifier.citationTam, C.C., Tam, C.C., Tam, C.C., Tam, C.C., Yeo, K.T., Yeo, K.T., Tee, N., Tee, N., Lin, R., Mak, T.M., Thoon, K.C., Thoon, K.C., Thoon, K.C., Jit, M., Yung, C.F., Yung, C.F., Yung, C.F. (2020). Burden and Cost of Hospitalization for Respiratory Syncytial Virus in Young Children, Singapore. Emerging Infectious Diseases 26 (7) : 1489-1496. ScholarBank@NUS Repository.
dc.description.abstractRespiratory syncytial virus (RSV) is the most common cause of pediatric acute lower respiratory tract infection worldwide. Detailed data on the health and economic burden of RSV disease are lacking from tropical settings with year-round RSV transmission. We developed a statistical and economic model to estimate the annual incidence and healthcare cost of medically attended RSV disease among young children in Singapore, using Monte Carlo simulation to account for uncertainty in model param-eters. RSV accounted for 708 hospitalizations in children <6 months of age (33.5/1,000 child-years) and 1,096 in children 6-29 months of age (13.2/1,000 child-years). The cost of hospitalization was SGD 5.7 million (US $4.3 million) at 2014 prices; patients bore 60% of the cost. RSV-associated disease burden in tropical settings in Asia is high and comparable to other settings. Further work incorporating efficacy data from ongoing vaccine trials will help to determine the potential cost-effectiveness of different vaccination strategies. � 2020 Centers for Disease Control and Prevention (CDC). All rights reserved.
dc.publisherCenters for Disease Control and Prevention (CDC)
dc.sourceScopus OA2020
dc.contributor.departmentSAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
dc.contributor.departmentDEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
dc.description.sourcetitleEmerging Infectious Diseases
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3201_eid2607_190539.pdf1.33 MBAdobe PDF



Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.